Molecular Characteristics and Clinical Features of Adults with NUP98 Fusions in Acute Myeloid Leukemia

LUN Ya, HUANG Jing-cao, LONG Dan, WAN Fang-fang, DAI Yang, YANG Yan, ZHAO Ting-ting, LI Qing, WU Yu

Abstract

To determine the molecular characteristics and clinical features of patients with nucleoporin 98 (NUP98) fusion gene positive acute myeloid leukemia (AML) and the impact of coexistence of NUP98 fusion genes and other prognosis-related genes. Methods Samples of bone marrow or peripheral blood were collected from the adult patients with de novo AML and myelodysplastic syndrome (MDS) in our hospital from July 1st, 2014 to March 1st, 2017. NUP98 fusuion genes and their karyotype were detected by PCR. The AML patients with chromosome 11p15 rearrangement or NUP98 fusion genes were studied as the research group and the remaining AMLs in this period as the control group. Meanwhile, the control AML group was divided into low-risk, medium-risk and high-risk groups respectively. Through comparison, analyzing the hematological characteristics, CR rates, the frequency of coexpression with other prognosis-related genes, and over all survival were done between these NUP98 fusion gene positive AMLs and control. Results A total of 197 AML patients participated in this study, including 16 (8.1%) having NUP98 fusion genes and the first case of positive NUP98-topoisomerase1 (TOP1) fusion gene. The NUP98 positive AMLs were mainly M2 and M5 in FAB classifications. Fms-like tyrosine kinase-3 (FLT3)-internal tandem duplication (ITD)(FLT3-ITD) occurred[31.25% (5/16)] and mortality[80.00% (4/5)] of the patients with NUP98 positive AMLs, higher than control group[occurred:9.95% (19/181), mortality:42.11% (8/19), P<0.05]. The CR rate of the study group induced chemotherapy was 78.57%,higher than the control group and the middle, high and middle rick control group. The median overall survival (OS) and leukemia free survival (LFS) of the patients with NUP98 positive AMLs were 13 months and 5 months, respectively. Conclusion NUP98 fusion positive AMLs have high level of coexistence with other prognostic-related genes, especially FLT3-ITD, leading to poor prognosis, short survival.

 

Keywords: Acute myeloid leukemia, NUP98-HOXA9, NUP98-NSD1, NUP98-TOP1, FLT3-ITD

 

Full Text:

PDF


References


GOUGH SM, SLAPE Cl, APLAN PD. NLT98 gene fusions and hematopoietic malignancies; common themes and new biologic insights. Blood.2011,118(24) :6247-6257.

DE THE H, LE BRAS M. LALLEMAND-BREITENBACH V. The cell biology of disease; acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol, 2012, 198 (1):11-21.

READER JC, MEEKINS JS, GOJO I, et al. A novel NUP98-PHF23 fusion resulting from a cryptic translocation t( 11; 17) (pl5; pl3) in acute myeloid leukemia. Leukemia, 2007,21(4);842-844.

CHOU WC, CHEN CY, HOU HA, et al. Acute myeloid leukemia bearing t(7; 11) (pl5;pl5) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile; comparative analysis of 493 adult patients. Leukemia, 2009 , 23(7):1303-1310.

NISHIYAMA M, ARAI Y. TSUNEMATSU Y. et al. 11 pi5 translocations involving the NUP98 gene in childhood therapy-related acute myeloid leukemia/ myelodysplastic syndrome. Genes Chromosomes Cancer, 1999, 26 ( 3 ); 215- 220.

CRESCENZI B, NOFRINI V, BARBA G, et al. NLT98/ 11 pi5 translocations affect CD34 + cells in myeloid and T lymphoid leukemias. Leuk Res,2015,39( 7); 769-772.

JAJU RJ, FIDLER C, HAAS OA, et al. A novel gene, NSDl, is fused to NUP9S in the t(5; 11)(q35;pl5. 5) in de novo childhood acute myeloid leukemia. Blood,2001, 98(4) : 1264-1267.

AHUJA HG, FELIX CA, APLAN PD. The t( 11 ;20)(pl5; qll) chromosomal translocation associated with therapy- related myelodysplastic syndrome results in an NL/P98-TOP1 fusion. Blood.1999,94(9): 3258-3261.

TAKEDA A. YASEEN NR. Nucleoporins and nucleocytoplasmic transport in hematologic malignancies. Semin Cancer Biol.2014,27;3-10[2017-06-25]. https://doi. org/10. 1016/j. semcancer. 2014. 02. 009.

KALVERDA B. PICKERSGILL H, SHLOMA VV, et al. Nucleoporins directly stimulate expression of developmental and cell-cycle genes inside the nucleoplasm. Cell. 2010, 140 (3):360-371.

WEI S, WANG S, QIU S, et al. Clinical and laboratory studies of 17 patients with acute myeloid leukemia harboring t (7; 11) ( p 15; pl5) translocation. Leuk Res, 2013, 37 ( 9); 1010-1015.

FRANKS TM, HETZER MW. The role of Nup9S in transcription regulation in healthy and diseased cells. Trends Cell Biol.2013.23(3): 112-117.

FUNASAKA T, NAKANO H, WU Y, et al. RNA export factor RAE1 contributes to Nl/P98-HOXA9-mediated leukemogenesis. Cell Cycle,2011,10(9): 1456-1467.

SHIMA Y, YUMOTOM. KATSUMOTO T, et al. MLL is essential for iVLfP98-HOXA9-induced leukemia. Leukemia, 2017,31(10):2200-2210.

BURILLOSANZ S, MORALES-CAMACHO RM, CABALLERO VELAZQUEZ T. et at. NUP9S-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid- committed cell and induces HOXA5, EVI1, FLT3, and MEISl expression. Int J Lab Hematol,2016,38( 1):64-71.

OSTRONOFF F, OTHUS M, GERBING RB, et al. NUP9S/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure; a COG and SWOG report. Blood. 2014, 124 ( 15); 2400-2407.

ARAI Y, HOSODA F, KOBAYASHI H, et at. The inv (11) (pi 5q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, NUP98, with the putative RNA helicase gene, DDX10. Blood. 1997,89( 11) ;3936-3944.

POTENZA L. SINIGAGLIA B, LUPPI M, et al. A t(11; 20)(pl5;qll) may identify a subset of nontherapy-related acute myelocytic leukemia. Cancer Genet Cytogenet, 2004, 149(2);164-168.

FORRESTER AM, GRABHER C, MCBRIDE ER, et al. NLTP98-HOXA9-transgenic zebrafish develop a myeloproliferative neoplasm and provide new insight into mechanisms of myeloid leukaemogenesis. Br J Haematol, 2011,155(2):167-181.

YASSINER, ABDUL-NABI AM. TAKEDA A, et al. Effects of the NUP98-DDX10 oncogene on primary human CD34+ cells: role of a conserved helicase motif. Leukemia, 2010,24(5); 1001-1011.


Refbacks

  • There are currently no refbacks.